Resultats globals: 1 registres trobats en 0.02 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
1.
21 p, 1.8 MB Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma / Rodriguez Blanco, J. (University of Miami. Miller School of Medicine) ; Pednekar, L. (University of Miami. Miller School of Medicine) ; Penas Pérez, Clara (University of Miami. Miller School of Medicine) ; Li, B. (University of Miami. Miller School of Medicine) ; Martin, V. (Universidad de Oviedo. Departamento de Morfología y Biología Celular) ; Long, J. (University of Miami. Miller School of Medicine) ; Lee, E. (Department of Cell and Developmental Biology, Vanderbilt University) ; Weiss, WA. (Department of Neurobiology, University of California) ; Rodriguez, C. (Universidad de Oviedo. Departamento de Morfología y Biología Celular) ; Mehrdad, N. (University of Miami, Miller School of Medicine) ; Nguyen, DM. (University of Miami, Miller School of Medicine) ; Ayad, N. G (University of Miami. Miller School of Medicine) ; Rai, P. (University of Miami, Miller School of Medicine) ; Capobianco, AJ. (University of Miami. Miller School of Medicine) ; Robbins, D. J. (University of Miami. Miller School of Medicine)
The SMOOTHENED inhibitor vismodegib is FDA approved for advanced basal cell carcinoma (BCC), and shows promise in clinical trials for SONIC HEDGEHOG (SHH)-subgroup medulloblastoma (MB) patients. Clinical experience with BCC patients shows that continuous exposure to vismodegib is necessary to prevent tumor recurrence, suggesting the existence of a vismodegib-resistant reservoir of tumor-propagating cells. [...]
2017 - 10.1038/onc.2017.232
Oncogene, Vol. Epub (2017)  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.